This year, Davos, Switzerland, will host some of the world's most prominent psychedelic industry leaders and researchers in a separate satellite event that will run parallel to the World Economic Forum.
From May 21 to 26 the Medical Psychedelic Series at Davos will feature industry executives, drug development experts, clinicians, nonprofit organizations, advocates and influencers from the psychedelics space.
Every year the Swiss ski resort town of Davos becomes a main stage for the annual meeting of the World Economic Forum, an international organization consisting of some of the world's most influential investors, business and political leaders, academics, celebrities and journalists.
The Forum's usual meeting dates of January were moved to May this year due to the outbreak of the Omicron variant of COVID - 19. After the 2020 outbreak of the virus, this year's meeting marks a return to in-person events.
The series will be held in the Medical Psychedelics House of Davos on the same dates as the World Economic Forum. The ultimate goal is to demonstrate the clinical efficacy of psychedelic treatments to global leaders in town.
The series will be an opportunity for the entire industry to showcase its therapeutic and economic potential, as it is owned by Energia Holdings, a company that invests in preventative care.
Marik Hazan, CEO of Energia Holdings Incorporated, said this is a one-of-a-kind opportunity for the medical psychedelics ecosystem to share the breakthroughs in psychedelics for the first time with world leaders.
The series will feature educational talks and panels from some of the best-known figures in the psychedelics space including Deepak Chopra, Jason Silva, Amanda Fielding, David Nichols, Rachel Yehuda and many others.
The conversations will focus on the FDA approval, policy, safety and efficacy, biocultural preservation, drug development pipelines and patient access to psychedelic compounds as approved and regulated medicines.
Maria Velkova, the managing partner of Tabula Rasa Ventures, said that they want to spark conversations about the high unmet need in mental health, the future of regulatory approval for psychedelic-assisted therapy, and build trust with the global community.